Physician profile
Chhaya Batra
NPI 1659464667
$831.58
in general payments reported to CMS, 2019-2025
15 companies · $171 in 2025
The $171 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $120 · 2021: $137 · 2022: $91.77 · 2023: $50.29 · 2024: $136 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $357.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $187.21 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Kaleo, INC. | $111.07 | 2019-2023 | Auvi-Q |
| Pfizer INC. | $86.99 | 2020-2024 | |
| Sanofi Pasteur INC. | $86.39 | 2019-2025 | |
| Sobi, INC | $73.15 | 2019-2022 | |
| Organon LLC | $62.47 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.13 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $36.75 | 2025 | Neffy |
| Alk-Abello, INC | $34.83 | 2024-2025 | Neffy, Grastek, Ragwitek |
| Aytu Biopharma, INC. | $29.99 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $22.31 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $16.56 | 2024 | Flumist Quadrivalent |
| Arbor Pharmaceuticals, INC. | $14.79 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.27 | 2021 | |
| Adlon Therapeutics L.P. | $11.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chhaya Batra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.